Similar Papers

Paper Title
Journal
Date
Author
Abstract ED12-1: Pol-theta inhibitors in HRD tumors
Cancer Research | VOL. 83
01 Mar 2023
Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
Fengping Shao ... Liqun Liu
Bioscience Reports | VOL. 40
Fengping Shao, et. al.Fengping Shao ... Liqun Liu
18 Mar 2020
A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer.
Zakaria Alameddine ... Ghada Araji
Current oncology (Toronto, Ont.) | VOL. 30
Zakaria Alameddine, et. al.Zakaria Alameddine ... Ghada Araji
19 Oct 2023
Abstract CT169: First-in-human, phase 1/2 study of GSK4524101, an oral DNA polymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors
Vivek Samnotra ... Haluk Yuzugullu
Cancer Research | VOL. 84
Vivek Samnotra, et. al.Vivek Samnotra ... Haluk Yuzugullu
05 Apr 2024
View more papers

More From: European Journal of Cancer

Paper Title
Journal
Date
Author
Cancer-Specific Utility Instrument for Health Economic Evaluations: A Synopsis of the EORTC QLU-C10D User Manual and Current Validity Evidence
Simone Seyringer ... Eva M Gamper
European Journal of Cancer | VOL. -
Simone Seyringer, et. al.Simone Seyringer ... Eva M Gamper
01 Jan 2025
Editorial Board
-
European Journal of Cancer | VOL. 215
--
01 Jan 2025
Incidence and survival of European adolescents and young adults diagnosed with sarcomas: EUROCARE-6 results
Annalisa Trama ... Salvatore Provenzano
European Journal of Cancer | VOL. -
Annalisa Trama, et. al.Annalisa Trama ... Salvatore Provenzano
01 Jan 2025
Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: analysis of individual patient-level data from daratumumab clinical trials
Kwee Yong ... Binod Dhakal
European Journal of Cancer | VOL. 215
Kwee Yong, et. al.Kwee Yong ... Binod Dhakal
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.